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Abstract
Background: Idiopathic normal pressure hydrocephalus (iNPH) is a potentially reversible cause of dementia and
gait disturbance that is typically treated by operative placement of a ventriculoperitoneal shunt. The outcome from
shunting is variable, and some evidence suggests that the presence of comorbid Alzheimer’s disease (AD) may
impact shunt outcome. Evidence also suggests that AD biomarkers in cerebrospinal fluid (CSF) may predict the
presence of AD. The aim of this study was to investigate the relationship between the phosphorylated tau/amyloid
beta 1-42 (ptau/Ab1-42) ratio in ventricular CSF and shunt outcome in patients with iNPH.
Methods: We conducted a prospective trial with a cohort of 39 patients with suspected iNPH. Patients were
clinically and psychometrically assessed prior to and approximately 4 months after ventriculoperitoneal shunting.
Lumbar and ventricular CSF obtained intraoperatively, and tissue from intraoperative cortical biopsies were
analyzed for AD biomarkers. Outcome measures included performance on clinical symptom scales, supplementary
gait measures, and standard psychometric tests. We investigated relationships between the ptau/Ab1-42 ratio in
ventricular CSF and cortical AD pathology, initial clinical features, shunt outcome, and lumbar CSF ptau/Ab1-42
ratios in the patients in our cohort.
Results: We found that high ptau/Ab1-42 ratios in ventricular CSF correlated with the presence of cortical AD
pathology. At baseline, iNPH patients with ratio values most suggestive of AD presented with better gait
performance but poorer cognitive performance. Patients with high ptau/Ab1-42 ratios also showed a less robust
response to shunting on both gait and cognitive measures. Finally, in a subset of 18 patients who also underwent
lumbar puncture, ventricular CSF ratios were significantly correlated with lumbar CSF ratios.
Conclusions: Levels of AD biomarkers in CSF correlate with the presence of cortical AD pathology and predict
aspects of clinical presentation in iNPH. Moreover, preliminary evidence suggests that CSF biomarkers of AD may
prove useful for stratifying shunt prognosis in patients being evaluated and treated for this condition.
Keywords: Alzheimer’s disease, Normal pressure hydrocephalus, Ventriculoperitoneal shunting, Tau, Amyloid beta
1-42, Cerebrospinal fluid
Background
Idiopathic normal pressure hydrocephalus (iNPH) is a
potentially reversible cause of cognitive and motor
impairment in older adults. The most widely-used and
proven current treatment is placement of a
ventriculoperitoneal (VP) shunt. While rates of response
to treatment with VP shunts are encouraging, the fac-
tors that predict shunt unresponsiveness remain poorly
understood. One potential contributor to shunt unre-
sponsiveness is the presence of comorbid neurologic
conditions that are common in aging, such as Alzhei-
mer’s disease (AD). Studies investigating the influence of
comorbid AD pathology on shunt outcome have pro-
duced conflicting results. Some evidence indicates that
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shunting in patients with iNPH [1], while other data
suggest that patients with the clinical features of iNPH
benefit from shunting irrespective of the presence of AD
pathology [2-4]. We recently reported data indicating
that the presence of amyloid beta 1-42 (Ab1-42) and
tau–the pathologic hallmarks of AD–in cortical biopsies
obtained at the time of shunt placement is associated
with poorer response to shunting in patients with sus-
pected iNPH [1].
Mounting evidence suggests that levels of amyloid
beta and tau obtained from cerebrospinal fluid (CSF)
samples may be used to identify patients with pathologi-
cal changes indicative of AD at autopsy [5,6]. Amyloid
beta 1-42 and hyperphosphorylated tau (ptau) have been
more specifically implicated in the underlying pathologi-
cal mechanisms of Alzheimer’s disease, and the ratio of
ptau/Ab1-42 has been shown to accurately predict the
presence or absence of AD [5]. Based on our prior
observation of the relationship between cortical AD
pathology and shunt unresponsiveness, we predicted
that levels of these biomarkers in CSF may differentiate
iNPH patients who respond well to shunting from those
who do not.
The placement of a shunt in patients with suspected
iNPH provides an opportunity to obtain and analyze
ventricular CSF. We investigated the relationships
between the ptau/Ab1-42 ratio in ventricular CSF and
cortical AD pathology, baseline presentation, and post-
surgical outcome of patients with suspected iNPH. We
predicted that there would be a strong correlation
between this ratio and cortical biomarker levels. We
further predicted that ratio values suggestive of higher
levels of AD pathology would be associated with poorer




This study was approved by the Institutional Review
Board of the University of Pennsylvania. All subjects
gave informed consent prior to participation. The
patients ranged in age from 64 to 85 years (mean = 75,
SD = 5.8). Education ranged from 12 to 20 years (mean
= 14, SD = 2.5). Patient and caregiver estimated disease
duration ranged from 1 to 16 years (mean = 3, SD =
2.6). Diagnosis of iNPH required the following: 1) Pre-
sence of two of the following symptoms or signs: a) a
progressive “magnetic” gait impairment, b) progressive
urinary incontinence, and c) progressive cognitive
impairment, and 2) ventriculomegaly on head computer-
ized tomography (CT) scan or brain magnetic resonance
imaging (MRI) out of proportion to generalized atrophy
with an Evan’sI n d e x≥ 0.3 [7]. Exclusion criteria
included comorbid neurologic or psychiatric conditions
and cognitive performance that was too poor to allow
for assessment of meaningful change (this criterion was
included in order to avoid statistical floor effects). Over
a 33-month period, 78 individuals were referred for eva-
luation; 47 were diagnosed with iNPH and underwent
surgery; 39 met both study inclusion and exclusion cri-
teria, were enrolled and had ventricular CSF analyzed
after shunting. Of the 8 that were not enrolled, 2
declined to participate in the study, 2 demonstrated
poor cognitive performance, and 4 had comorbid neuro-
logic or psychiatric conditions. Thirty of the 39 enrolled
subjects followed up and were evaluated postoperatively.
Of the 9 enrolled subjects who did not follow up, three
experienced unrelated health complications that prohib-
ited follow-up (one of these died), three experienced
surgical complications from shunt placement that pre-
vented outpatient evaluation (one of these died), and
three declined for reasons unrelated to their health
status.
Clinical assessment
Study participants were assessed prior to surgery and
approximately 4 months postoperatively (mean = 120
days; SD = 30 days) by a single behavioral neurologist.
Clinical symptom severity was rated using a 15-point
NPH Scale [8] consisting of three five-point subscales
describing deficits in gait, cognition, and bladder control
(3 = profoundly impaired, 15 = normal). Supplemental
gait measures included time to walk 50 feet (in seconds),
number of steps required to turn 180 degrees, and over-
all quality of gait as judged by the neurologist on a 5-
point scale ranging from 0 (normal) to 4 (non-ambula-
tory) [9]. Cognitive evaluation was performed using a
psychometric battery comprised of the WMS-III logical
memory subtest, a 10-item word list recall task, digit
span forward and reversed, category fluency, Boston
Naming Test (first 30 items), trail making (A & B; total
time and errors), digit symbol, and clock draw and copy.
Patient performance was normalized (using Z-scores)
relative to that of 202 age- and education-matched nor-
mal control subjects who participate in research at the
Penn Memory Center. A global composite measure of
psychometric performance was created by averaging the
Z-scores. In a small number of sessions, one or more
psychometric tests could not be performed due to cog-
nitive or behavior problems, physical impediments, or
verbal refusal on the part of patients.
Shunting, tissue biopsy and analysis, and CSF acquisition
and analysis
Strata II programmable valves (Medtronic, Inc., Minnea-
polis, MN, USA) with an initial setting of 1.5 were used
in this study. All shunts were placed in the right
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sue (approximately 0.5 cm
3) was biopsied at the site of
shunt entry. There were no surgical complications asso-
ciated with biopsy acquisition. The biopsied tissue was
immersion fixed in neutral buffered formalin overnight
followed by paraffin embedding. Six-micrometer-thick
sections were stained with hematoxylin and eosin for
neuropathological examination, and with thoflavin S for
identification of neuritic plaques and neurofibrillary tan-
gles. Sections were also immunohistochemically labeled
for Ab plaques (NAB228, a mouse monoclonal antibody
raised against Ab1-11 synthetic peptide) [10], hyperpho-
sphorylated tau for neurofibrillary tangles and dys-
trophic neurites (PHF1) [11], alpha-synuclein for Lewy
bodies and Lewy neurites (SYN303) [12], and TDP-43
for pathological inclusions (rabbit polyclonal antibody;
Protein-Tech Group, Chicago, IL, USA) with methods
as previously described [13]. Control sections processed
without primary antibodies were included in all runs
and displayed no specific staining. Sections obtained
from patients with autopsy-confirmed AD were used as
positive controls. Semiquantitative scores were assigned
corresponding to the densities of neurofibrillary tangles
and Ab plaques (as assessed by immunohistochemistry),
and to neuritic plaques (as assessed by thioflavin S
stain). Scores were as follows: absent = 0; rare = 0.5; low
= 1; moderate = 2; and high = 3. Neuritic plaque scores
were based on Consortium to Establish a Registry for
Alzheimer’s Disease criteria [14].
Ventricular CSF samples (approximately 25 cc) were
obtained intraoperatively. For a subset of 18 patients,
lumbar CSF was also collected by lumbar puncture (LP)
performed either during the course of outpatient clinical
evaluation (two patients; approximately 40 cc) or intrao-
peratively (16 patients; approximately 5-10 cc; after
administration of anesthesia, but before shunt place-
ment). The times between lumbar and ventricular CSF
collection for the two patients who had LP during out-
patient clinical evaluation were 21 and 121 days. All
samples were analyzed for total tau, phosphorylated tau
and beta amyloid-42 levels using the xMAP multiplex
immunoassay on the Luminex platform (Luminex Cor-
poration, Austin, TX, USA) using Innogenetics (INNO-
BIA AlzBio3; Ghent, Belgium) research reagents. These
reagents included monoclonal antibodies specific for
Ab1-42 (4D7A3), total tau (AT120) and ptau (AT270)
[5].
Statistical analysis
To evaluate for potential selection bias, two sample t-
tests were performed to compare patients who followed
up with those that did not with respect to age, educa-
tion, estimated disease duration, baseline performance
on clinical symptom scales, supplemental gait measures,
and psychometric tests, and ventricular and lumbar CSF
biomarker levels. Paired t-tests were used to determine
whether the cohort of patients who completed the study
improved in response to shunting. A one-sample t-test
was used to evaluate percent change in gait time. Logis-
tic regression was performed using forward selection
with an entry p value of 0.25 to determine which of the
three ventricular CSF biomarkers were most useful in
predicting the presence of cortical pathology. Receiver
operating characteristic (ROC) analysis was performed
to determine the optimal ptau/Ab1-42 cutoff for differ-
entiating between patients with cortical AD pathology
and those without. Standard decision statistics such as
the area under the ROC curve (AUC), specificity, and
sensitivity were generated by means of a logistic regres-
sion model [15]. In order to ensure that the effect of the
ptau/Ab1-42 ratio in predicting cortical pathology was
not confounded by age, education, and disease duration,
Pearson correlations were run between the ratio and
these variables. Based on the cutoff level, the cohort was
then divided into low (n = 17) and high (n = 22) ratio
groups. For each study measure, a two sample t-test was
performed to assess the influence of biomarker ratio on
baseline performance. The influence of biomarker level
on shunt response was assessed using a repeated mea-
sures ANOVA for each study measure with study mea-
sure as the dependent variable and pre/post surgical
status (within subject) and ratio group (between subject)
as the independent variables. A two sample t-test was
used to determine if the percent change in gait time was
dependent on biomarker levels. Finally, Pearson correla-
tions were employed to investigate the relationship
between the ventricular and lumbar levels of ptau/Ab1-
42 in the subset of patients who underwent LP. Regres-
sion parameters for predicting lumbar CSF ratio values
from ventricular CSF ratio values were also determined.
Statistical analysis was performed using SAS Software
(Version 9.2, SAS Institute Inc., Cary, NC, USA). All sta-
tistical tests were two-sided with a 0.05 significance level
unless otherwise indicated.
Results
Baseline characterization and shunt response of entire
cohort
At baseline, the mean NPH scale total score was 9.5 (N
= 39; SD = 1.7). The mean subscale scores were as fol-
lows: mean gait score = 3.2 (N = 39; SD = 0.7), mean
cognition score = 3.6 (N = 39; SD = 0.6), and mean
incontinence score = 2.8 (N = 38; SD = 1.1). The distri-
bution of subscale scores is shown in Table 1. Of the 39
patients tested at baseline, 32 (82%) presented with the
full triad of symptoms. The mean quality of gait scale
score was 1.6 (N = 38; SD = 0.9). The mean global com-
posite Z-score at baseline was -1.0 (N = 33; SD = 0.6).
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performance on the cognition subscale of the NPH scale
(t = 2.69, df = 37, p = 0.011) and trended toward poorer
performance on the global composite Z-score (t = 1.92,
df = 31, p = 0.064) compared to the group of patients
who did not follow up (see Additional file 1 for detailed
statistical results for all variables that were analyzed).
No other statistically significant differences between
these two groups were observed. In subsequent analyses
detailed below, all 39 patients were divided into a group
with a high ptau/Ab1-42 ratio in ventricular CSF and a
group with a low ptau/Ab1-42 ratio, using a statistically
determined cutoff value. Of the 9 patients who did not
complete the study, 4 were in the low ratio group and 5
were in the high ratio group.
For patients who followed up, there was significant
improvement between baseline and postoperative per-
formance on the NPH scale total score (t = 6.16, df =
29, p < 0.001), all of its subscales (Gait t = 6.11, df = 29,
p < 0.001; Cognition t = 3.75, df = 29, p = 0.001; Incon-
tinence t = 5.07, df = 28, p < 0.001), quality of gait (t =
3.53, df = 29, p = 0.001), proportional change in gait
time (t = 3.10, df = 28, p = 0.004), and global composite
Z-score (t = 3.99, df = 20, p = 0.001). Of the component
tests of the global composite, there was significant
improvement in category fluency (t = 2.78, df = 28, p =
0.01) and digit symbol (t = 2.87, df = 26, p = 0.008) and
a trend towards improvement in trails A time (t = 1.84,
df = 28, p = 0.077). (Additional file 2 shows the statisti-
cal test results for improvement on all instruments.)
Relationship between ventricular CSF biomarker levels
and cortical AD pathology
In the 37 patients who underwent cortical biopsy, 25
(67.6%) demonstrated evidence of one or more AD
pathologic markers, while 12 (32.4%) showed no evi-
dence of AD pathology. In the 39 patients who had ven-
tricular CSF analyzed: mean Ab1-42 value was 121 pg/
ml (SD = 36, range = 37-234); mean total tau value was
306 pg/ml (SD = 155, range = 62-861); and mean ptau
value was 47 pg/ml (SD = 22, range = 10-109).
Logistic regression using forward selection revealed
that Ab1-42 (beta = -0.02, point estimate = 0.98, p =
0.043) and ptau (beta = 0.03, point estimate = 1.03, p =
0.122) were the most significant CSF biomarkers for
predicting the presence of cortical tissue pathology. T-
tests showed that the ventricular CSF ptau/Ab1-42 ratio
values differed significantly (t = 2.73, df = 35, p = 0.01)
between patients with cortical tissue pathology (mean =
0.45, SD = 0.21) and those with no cortical pathology
( m e a n=0 . 3 2 ,S D=0 . 1 )( F i g u r e1 A ) .R O Ca n a l y s i s
revealed the optimal ptau/Ab1-42 cutoff for differentiat-
ing patients with pathology from those without pathol-
o g yt ob e0 . 3 7( A U C=0 . 6 9 ,p = 0.025) (Figure 1B).
With this cutoff, sensitivity was 68% and specificity was
67%. Pearson correlation revealed no significant rela-
tionship between ventricular CSF ptau/Ab1-42 ratio and
education, age, or patient/caregiver estimated disease
duration (all p > 0.1).
Influence of ventricular biomarker levels on baseline
performance
Patients with higher CSF ptau/Ab1-42 ratio values
showed significantly poorer baseline performance on
Trails B time (t = 2.4, df = 32, p = 0.022) and digit sym-
bol (t = 2.27, df = 34, p =0 . 0 3 ) .T h i sg r o u pt r e n d e d
towards poorer performance on digit span backwards (t
= 1.9, df = 37, p = 0.065) and trails B errors (t = 1.88, df
= 32, p = 0.069). Patients with a ptau/Ab1-42 ratio >
0.37 showed better gait performance as assessed by the
quality of gait scale (t = 2.04, df = 36, p =0 . 0 4 9 )a n d
gait subscale of the NPH scale (t = 2.97, df = 37, p =
0.005). (See Additional file 3 for detailed statistical
results for all variables that were analyzed.)
Influence of ventricular biomarker levels on shunt
response
Significant interactions between session (pre/post sur-
gery) and ptau/Ab1-42 ratio group were observed for
the gait subscale of the NPH scale (F[1,28] = 8.09, p =
0.008), trails A time (F[1,27] = 4.56, p =0 . 0 4 2 ) ,w o r d
list memory trial 3 (F[1,28] = 6.89, p = 0.014), word list
recall (F[1,27] = 4.29, p = 0.048), and clock copy (F
[1,28] = 4.62, p = 0.040); in all cases, patients with a
higher ptau/Ab1-42 ratio showed less robust response
to shunting than those with a lower ratio. A t-test
revealed a significantly (t = 2.26, df = 27, p =0 . 0 3 2 )
lower percent change in gait time in the group with
higher ptau/Ab1-42 (mean = -8.3, SD = 33.4) compared
to the group with lower ptau/Ab1-42 (mean = -35.1, SD
= 28.3). (See Figure 2 and Additional file 4 which shows
detailed statistical results for all variables that were
analyzed.)
Table 1 Clinical presentation of cohort at baseline
Frequency (%)
Subscale Score Gait Cognition Incontinence
1 1 (2.56) 0 (0) 4 (10.53)
2 2 (5.13) 0 (0) 12 (31.58)
3 27 (69.23) 19 (48.72) 13 (34.21)
4 8 (20.51) 18 (46.15) 6 (15.79)
5 1 (2.56) 2 (5.13) 3 (7.89)
Clinical symptom severity was rated using a 15-point NPH scale comprised of
three five-point subscales describing deficits in gait, cognition, and bladder
control. Numbers in each cell indicate how many subjects in the cohort were
given a specific subscale score ranging from 5 (normal) to 1 (profoundly
impaired). Numbers in parentheses represent the percentage of the cohort
with a given NPH subscale score.
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and lumbar CSF spaces
The ratios of ptau/Ab1-42 were positively correlated (N
= 18, r = 0.63, p = 0.005) between ventricular and lum-
bar CSF samples. The ventricular CSF ptau/Ab1-42
ratio significantly predicted the lumbar CSF ptau/Ab1-
42 ratio (beta = 0.22, t(16) = 3.27, p = 0.005; intercept =
0.03, t(16) = 0.88, p = 0.392): ratiolumbar =0 . 2 2×r a t i o -
ventricular + 0.03.
Discussion
We investigated relationships between the ptau/Ab1-42
ratio in ventricular CSF and cortical AD pathology,
initial clinical features, shunt outcome, and lumbar CSF
ptau/Ab1-42 ratios in patients being shunted for iNPH.
We found that the ventricular CSF ptau/Ab1-42 ratio
differentiated patients with cortical AD pathology from
those without pathology with a sensitivity of 68% and a
specificity of 67% at the optimal cutoff point. Patients
with the highest levels of ventricular ptau/Ab1-42 (more
suggestive of AD) performed more poorly at baseline on
a variety of psychometric measures but performed better
on gait measures. Higher ptau/Ab1-42 ratios were asso-
ciated with poorer improvement in both cognition and
gait after shunting. Finally, we demonstrated a signifi-
cant correlation between ptau/Ab1-42 ratios in the ven-
tricular and lumbar CSF in a subset of our cohort,
suggesting that measures of lumbar ptau/Ab1-42 may
also correlate with patterns of baseline performance and
shunt outcomes in patients with suspected iNPH.
The impact of AD pathology on the specific cognitive
measures used in this study is informative. Improve-
ment in the entire cohort of subjects after shunting was
most significant on certain tests of executive function,
attention, and speeded psychomotor action (category
fluency, digit symbol, and trails A time), and not mem-
ory. Deficits in these cognitive domains (classically con-
sidered part of a constellation of frontostriatal or so-
called “subcortical” deficits) have long been associated
with iNPH [16], such that improvement in these areas
in response to shunting was expected. However, it is
notable that significant baseline differences were identi-
fied between subjects with high and low ptau/Ab1-42
ratios in ventricular CSF on measures that also tested
these aspects of cognition (Trails B, digit span and digit
symbol). The finding that comorbid AD pathology wor-
sens performance in these specific areas reinforces the
notion that it is difficult to disambiguate patients with
the clinical syndrome of iNPH from those with co-mor-
bid AD based on patterns of cognitive impairment. On
the other hand, the finding that patients with high ven-
tricular CSF ptau/Ab1-42 ratios have better baseline
gait performance suggests that cognitive symptoms tend
to predominate the overall clinical picture of those
patients who are affected by comorbid AD and iNPH.
The finding that patients with high ptau/Ab1-42 ratios
show less recovery of gait function after shunting is
accounted for at least partly by their higher baseline
gait performance compared to patients lacking comor-
bid AD pathology.
Figure 1 Stratification of subjects by cortical p-tau and Ab1-42 pathology. A) Ventricular ptau/Ab1-42 ratio values stratified by the presence
(path) or absence (no path) of cortical pathology. B) ROC curve for differentiation of the no path and path groups by the ventricular ptau/Ab1-
42 ratio. Error bars represent standard error, * p < 0.05, n = 37.
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post-shunt improvement mainly on tests of memory
(immediate and delayed word list recall) and visuospatial
function (clock copy)–cognitive domains that are typi-
cally impaired in patients with AD. In other words,
while the baseline cognitive profile of these patients may
Figure 2 Impact of ventricular CSF ptau/Ab1-42 ratios on outcome measures. Shunt outcome with respect to gait (A, B) and cognition (C-
F) stratified by high and low ptau/Ab1-42 ratio values. The high/low cutoff for the ratio was 0.37. Error bars represent standard error. * p < 0.05,
** p < 0.01.
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pathology from those without, their response to shunt-
ing may suggest selective failure of improvement in cog-
nitive domains typically associated with AD. Examining
individual psychometric measures more closely, there
also emerged an interesting dissociation between perfor-
mance on different memory tests in our battery. While
the ptau/Ab1-42 ratio made a difference with respect to
outcomes for verbal list learning, it did not impact logi-
cal memory performance. One possible explanation is
that the two tasks differ with respect to specific cogni-
tive demands. Evidence suggests that performance on
story memory tasks relies, to some extent, on intrinsic
semantic organization of the material, while word-list
memory tasks require subjects to self-generate organiza-
tional strategies between unrelated items [17]. Word list
memory is thus thought to rely more on executive func-
tion, a domain thought to be preferentially affected in
iNPH [16]. The finding that patients with low ptau/
Ab1-42 ratios show selective improvement in word list
recall is therefore potentially consistent with the idea
that iNPH may influence performance on word list
recall tasks to a greater extent than performance on
story memory tasks. However, the finding that baseline
logical memory performance did not differ significantly
between high and low ptau/Ab1-42 ratio groups was
somewhat unexpected, since more severe baseline
impairments in this area might have been predicted in
patients with AD pathology.
Our finding that total tau does not predict the pre-
sence of cortical AD pathology in patients with iNPH is
consistent with a previous study which found elevated
total tau levels in the lumbar CSF of patients with iNPH
and those with AD [18]. In addition, Tisell and collea-
gues [19] have investigated the relationship between
ventricular total tau levels and shunt outcome in iNPH,
reporting no significant relationship between total tau
and shunt response as assessed using measures of gait,
balance, alertness, and cognition. One likely explanation
for the difference between these findings and our own is
our use of a ratio of biomarkers that may be more spe-
cifically associated with AD pathological processes than
total tau. This is further supported by a study conducted
by Tarnaris and colleagues [20] that found that total tau
achieved a sensitivity of only 17% and a specificity of
only 20% for predicting favorable shunt outcome, as
assessed by determining the extent to which patients
demonstrated non-transient improvement and resump-
tion of pre-illness activity at 6 months. Interestingly, the
combination of total tau and Ab1-42 predicted favorable
outcome with a sensitivity of 80% and a specificity of
82.4%.
Ventricular CSF biomarker information, although not
available as part of a typical clinical outpatient
evaluation for iNPH, may potentially be used to guide
postoperative management for those patients who
receive magnetically programmable shunts. CSF AD bio-
marker data obtained intraoperatively may identify a
subset of patients for whom repeated shunt adjustments
are unlikely to yield clinical benefit, thus sparing those
patients from additional risk of overdrainage and other
complications. Bauman and colleagues [21] recently
observed that cortical pathology data may similarly
inform shunt management strategy. In addition, ventri-
cular biomarker levels consistent with AD may poten-
tially suggest that a patient previously presumed to have
iNPH should be re-evaluated and possibly treated for
AD.
Our finding that ptau/Ab1-42 ratios in the ventricular
and lumbar CSF are correlated suggests that lumbar
ptau/Ab1-42 may also predict baseline performance and
shunt outcome in patients with suspected iNPH. The
regression equation suggests that the optimal cutoff
ratio for the lumbar CSF is much smaller than the ven-
tricular CSF ratio. This is consistent with the findings of
Tarnaris and colleagues [22] that the levels of various
biomarkers, including total tau and Ab1-42, differ
between the ventricular and lumbar CSF. Although we
have provided a regression equation that predicts the
lumbar CSF ptau/Ab1-42 ratio from the ventricular
ratio, the optimal lumbar ratio cutoff should ideally be
determined by replicating our analysis in a larger sample
using lumbar CSF biomarkers directly.
This study has several limitations. One is its relatively
small sample size. In addition, a number of patients who
had received shunts to treat presumed iNPH did not
participate in the study, either because they were
excluded by the study criteria or because they failed to
follow up. Restriction of the patients participating in the
study in these ways may limit the generalizability of the
findings and may also have led to a degree of selection
bias. A comparison of baseline performance between
patients who completed the study versus those who
enrolled but did not complete the study reveals a statis-
tically significant difference in the cognitive subscale
measure of the NPH scale. Notably, this result was not
supported by performance on any individual psycho-
metric instrument. Nonetheless, this finding suggests
that patients who completed the study may have had
slightly worse baseline cognition than those who
dropped out. While we believe that the results of the
study are still valid and informative, we also acknowl-
edge that the data may be somewhat more informative
for patients who have cognitive impairments as part of
their presenting clinical picture. Finally, we assessed out-
come at 4 months following surgery. A longer time-
frame for assessment of outcome in these patients may
be more useful for gauging long-term outcome and we
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characteristics of these patients may evolve long after 4
months following surgery. However, given that the tem-
poral dynamics of post-surgical symptom improvement
in iNPH patients are not well characterized, these find-
ings do contribute meaningfully to what is currently
known about recovery of function after shunting.
Conclusions
To date, the underlying pathology and pathophysiology
of iNPH remain largely unknown. While the results of
this study are consistent with the notion that CSF ptau
and Ab1-42 are markers of co-morbid AD, it is also
possible that these indicators may, for some patients,
represent part of the pathological profile of iNPH as
well. Nevertheless, the results of this preliminary study
strongly suggest that their presence or absence in ventri-
cular CSF correlates with certain outcomes for patients
undergoing shunting. If our findings can be replicated in
larger samples, they would indicate that ventricular CSF
measures of ptau and Ab1-42, and possibly lumbar mea-
sures of these biomarkers, are potentially clinically use-
ful in predicting outcomes for patients being evaluated
for iNPH.
Additional material
Additional file 1: Assessment of potential selection bias. Analysis of
baseline measurements of patients lost to follow up compared with
those evaluated both pre and postoperatively. T-tests were performed to
test for baseline differences between the groups.
Additional file 2: Shunt response of entire cohort evaluated both
pre- and post operatively. Results of paired t-tests performed to test
for improvement of entire cohort in response to shunting. Note that
percent change in gait time was analyzed using a one-sample t-test.
Additional file 3: Relationship between ventricular CSF ptau/Ab1-42
ratio and baseline presentation. Results of t-tests performed to test for
baseline differences between the low and high ventricular CSF ptau/Ab1-
42 ratio groups. The cutoff value defining the low and high ratio groups
was 0.37.
Additional file 4: Relationship between ventricular CSF ptau/Ab1-42
ratio and shunt response. Results of repeated measures ANOVAs
performed to test for differences in shunt response between the low
and high ventricular CSF ptau/Ab1-42 ratio groups. Only the results for
the interaction between session (pre/post surgery) and ptau/Ab1-42 ratio
group are shown. Note that percent change in gait time was compared
between the two groups using a t-test.
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